Kura Oncology (NASDAQ:KURA) Stock Price Down 4.6% – Should You Sell?

Kura Oncology, Inc. (NASDAQ:KURA) shares traded down 4.6% during mid-day trading on Tuesday . The company traded as low as $11.00 and last traded at $11.10. 799,334 shares were traded during mid-day trading, a decline of 50% from the average session volume of 1,583,000 shares. The stock had previously closed at $11.64.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on KURA. Barclays reissued an “overweight” rating and set a $28.00 target price (up from $11.00) on shares of Kura Oncology in a report on Monday, November 24th. Zacks Research upgraded shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 5th. Guggenheim began coverage on shares of Kura Oncology in a research note on Thursday, September 4th. They set a “neutral” rating for the company. Citigroup reaffirmed a “market outperform” rating on shares of Kura Oncology in a report on Friday, December 5th. Finally, Wall Street Zen raised shares of Kura Oncology from a “sell” rating to a “hold” rating in a report on Sunday, August 17th. Eight equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $26.57.

Kura Oncology Stock Down 2.6%

The stock’s fifty day simple moving average is $10.58 and its 200-day simple moving average is $8.17. The stock has a market cap of $910.23 million, a P/E ratio of -4.22 and a beta of 0.21. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.12 and a current ratio of 5.12.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). The business had revenue of $20.75 million during the quarter, compared to analyst estimates of $17.48 million. Kura Oncology had a negative net margin of 208.48% and a negative return on equity of 65.42%. As a group, research analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Thomas James Doyle sold 4,539 shares of the stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $11.18, for a total transaction of $50,746.02. Following the sale, the senior vice president owned 130,257 shares in the company, valued at approximately $1,456,273.26. This trade represents a 3.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Brian T. Powl sold 8,887 shares of Kura Oncology stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $11.18, for a total value of $99,356.66. Following the completion of the transaction, the insider owned 139,689 shares in the company, valued at approximately $1,561,723.02. This represents a 5.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 122,675 shares of company stock valued at $1,196,657. Company insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC increased its stake in shares of Kura Oncology by 392.8% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock valued at $34,000 after acquiring an additional 3,072 shares in the last quarter. State of Wyoming bought a new stake in Kura Oncology in the first quarter valued at $48,000. PNC Financial Services Group Inc. increased its stake in Kura Oncology by 127.2% in the third quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock valued at $60,000 after purchasing an additional 3,769 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Kura Oncology by 471.3% during the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock valued at $70,000 after purchasing an additional 9,958 shares during the period. Finally, Pallas Capital Advisors LLC boosted its position in shares of Kura Oncology by 32.2% during the 2nd quarter. Pallas Capital Advisors LLC now owns 13,304 shares of the company’s stock worth $77,000 after purchasing an additional 3,241 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.